The evaluation of the therapeutic efficacy and tolerability of agomelatine (agomelatine) in a dose of 25-50 mg daily in 26 patients with moderate to severe non-psychotic level of endogenous depression. Study duration was 56 days. Reduction of the depressive symptoms was observed in all 26 patients. By the end of the study the formation of remission of depression on the scale of HDRS-21 was observed in 76.9% of patients. Side effects of the drug found in only one case had a mild severity, were reduced rapidly, they do not prevent the therapy. Results of the study showed that agomelatine has a high therapeutic antidepressant activity in the treatment of patients with endogenous depressions psychotic level of moderate to severe degree.
Conducted a 56-day study of clinical efficacy and tolerability of agomelatine (agomelatine) has convincingly shown that the drug has a high therapeutic antidepressant activity in the treatment of patients with endogenous depressions psychotic level of moderate to severe degree.
A feature of the drug is the early onset of therapeutic effect, which is clearly manifested in the first 2 weeks of treatment, achieving a significant degree of severity by the 4th week of treatment and decreased in the later stages of its use. By the end of the study the formation of remission on a scale of HDRS-21 depression was observed in 76.9% of the surveyed patients. It should be noted that these data are consistent with results of previous works.
Doubtless advantage of the drug – the balanced nature of the action, comprising actual timolepticheskoe, anxiolytic, stimulating effects, it can be used for depression various clinical patterns, namely the affect of melancholy, anxiety, apathy, adynamic symptoms, while the final results studied the effects are similar in degree.
Side effects of agomelatine have a low incidence of, minimal in severity and usually transitory, do not require discontinuation of the drug, which is possibly due to the absence or weak expression of its ability to bind to a number of receptors, particularly serotonin 5-HT1A, 5-HT2-receptors, D1- and D2-dopamine receptors, α1-, α2-, ß-adrenergic, histamine H1-receptor, cholinergic receptors, benzodiazepine and opioid receptors. It should be noted that agomelatine can be used successfully in patients burdened with physical illnesses, so it does not cause them to relapse.
Thus, the features of the spectrum of action of agomelatine can effectively use it in the treatment of different degrees of severity, and clinical manifestations of endogenous depression. The speed of onset of therapeutic effect, maintaining it at a high level during further treatment, a favorable profile of adverse events and their minor severity, as well as short existence -nesomnennye benefits of the drug.
The emergence of a new melatoninergic antidepressant agomelatine (agomelatine), allows you to expand the treatment options for patients with depressive disorders and sleep disorders spectrum, to prevent recurrence of the disease.